organization · Reporting owner

Newtyn Management, LLC

Disclosed activity across 5 companies

Tapewire entity: 117350
SEC CIK: 0001569241

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Flexion Therapeutics IncFLXN · Entity 16545	10% owner	November 19, 2021	November 23, 2021
MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770	See Remarks	January 12, 2023	January 17, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Flexion Therapeutics Inc

Report date November 19, 2021 · Filed November 23, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2021-11-19 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-11-19 · Other · Disposed 5,900,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: The shares are held directly by Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE"). Newtyn Management, LLC, as the investment manager to NP and NTE, possesses the sole power to direct the vote and the sole power to direct the disposition of the securities held by NP and NTE. Newtyn Management, LLC disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, NP, NTE or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.

F2: The shares are held directly by Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE"). Newtyn Management, LLC, as the investment manager to NP and NTE, possesses the sole power to direct the vote and the sole power to direct the disposition of the securities held by NP and NTE. Newtyn Management, LLC disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, NP, NTE or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

MERRIMACK PHARMACEUTICALS INC

Report date January 12, 2023 · Filed January 17, 2023

Jointly reported with Levy Noah G., NEWTYN PARTNERS, LP, NEWTYN TE PARTNERS, LP, Newtyn Capital Partners, LP, Ledo Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,119,586	Reported balance After 2023-01-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-01-12 · Purchase · Acquired 100,000 · Balance 1,119,586 F1: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Garrett Motion Inc.

Report date April 30, 2021 · Filed May 04, 2021

Jointly reported with NEWTYN PARTNERS, LP, NEWTYN TE PARTNERS, LP, Newtyn Capital Partners, LP, Ledo Capital, LLC, Levy Noah G.

Section 16 reporting ended · disclosed 2021-05-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2021-04-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-04-30 · Other · Disposed 1,802,095 · Balance 0 F1: On September 20, 2020, Garrett Motion Inc. (the "Issuer") and certain of its subsidiaries (collectively, the "Debtors") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). On April 26, 2021, the Debtors filed an amended Chapter 11 plan of reorganization (the "Plan") and on April 9, 2021, the Issuer filed a supplement to the Plan (as amended on April 20, 2021 and April 22, 2021, the "Plan Supplement") with the Bankruptcy Court. On April 26, 2021, the Bankruptcy Court entered an order confirming the Plan (the "Confirmation Order") and, on April 30, 2021 (the "Effective Date") the conditions to effectiveness of the Plan were satisfied or waived and the Issuer emerged from bankruptcy. F2: (Continued from footnote 1) On the Effective Date, all outstanding shares of the Issuer's common stock outstanding prior to the Effective Date were canceled, released, and extinguished, and of no further force or effect and without any need for a holder of such common stock to take further action with respect thereto. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Persons with respect to the Issuer. F3: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly held 1,117,299 and 684,796 shares, respectively, of common stock of the Issuer. Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons."

Filing footnotes · ownership attribution and instrument terms

F1: On September 20, 2020, Garrett Motion Inc. (the "Issuer") and certain of its subsidiaries (collectively, the "Debtors") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). On April 26, 2021, the Debtors filed an amended Chapter 11 plan of reorganization (the "Plan") and on April 9, 2021, the Issuer filed a supplement to the Plan (as amended on April 20, 2021 and April 22, 2021, the "Plan Supplement") with the Bankruptcy Court. On April 26, 2021, the Bankruptcy Court entered an order confirming the Plan (the "Confirmation Order") and, on April 30, 2021 (the "Effective Date") the conditions to effectiveness of the Plan were satisfied or waived and the Issuer emerged from bankruptcy.

F2: (Continued from footnote 1) On the Effective Date, all outstanding shares of the Issuer's common stock outstanding prior to the Effective Date were canceled, released, and extinguished, and of no further force or effect and without any need for a holder of such common stock to take further action with respect thereto. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Persons with respect to the Issuer.

F3: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly held 1,117,299 and 684,796 shares, respectively, of common stock of the Issuer. Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons."

PACIFIC GAS & ELECTRIC Co

Report date February 01, 2023 · Filed February 03, 2023

Section 16 reporting ended · disclosed 2023-02-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
First pref stock, par value $25, 6% nonredeemableSEC Table I · non-derivative	IndirectSee Footnote	151,396	Last balance in matching sequence After 2023-02-02 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2023-02-01 · Sale · Disposed 12,500 · Balance 169,336 F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities. Row 5 · 2023-02-02 · Sale · Disposed 17,940 · Balance 151,396 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.69 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.
First pref stock, par value $25, 5.50% nonredeemableSEC Table I · non-derivative	IndirectSee Footnote	240,477	Last balance in matching sequence After 2023-02-02 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2023-02-01 · Sale · Disposed 901 · Balance 241,477 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.61 to $19.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities. Row 6 · 2023-02-02 · Sale · Disposed 1,000 · Balance 240,477 F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.
First pref stock, par value $25, 5% redeemableSEC Table I · non-derivative	IndirectSee Footnote	150,537	Last balance in matching sequence After 2023-02-02 transaction · row 7 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 3 · 2023-02-01 · Sale · Disposed 650 · Balance 152,037 F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities. Row 7 · 2023-02-02 · Sale · Disposed 1,500 · Balance 150,537 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.94 to $18.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.
First pref stock, par value $25, 4.36% series A redeemableSEC Table I · non-derivative	IndirectSee Footnote	102,988	Last balance in matching sequence After 2023-02-02 transaction · row 9 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 4 · 2023-02-01 · Sale · Disposed 1,000 · Balance 103,488 F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities. Row 9 · 2023-02-02 · Sale · Disposed 500 · Balance 102,988 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.
First pref stock, par value $25, 5% series A redeemableSEC Table I · non-derivative	IndirectSee Footnote	65,061	Reported balance After 2023-02-02 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2023-02-02 · Sale · Disposed 4,930 · Balance 65,061 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.795 to $17.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.
First pref stock, par value $25, 5% nonredeemableSEC Table I · non-derivative	IndirectSee Footnote	30,402	Reported balance Holding disclosure · report date 2023-02-01 · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · Balance 30,402 F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.
First pref stock, par value $25, 4.80% redeemableSEC Table I · non-derivative	IndirectSee Footnote	135,755	Reported balance Holding disclosure · report date 2023-02-01 · row 11 Holding and transaction disclosures are not merged. 1 source row Row 11 · Balance 135,755 F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.
First pref stock, par value $25, 4.50% redeemableSEC Table I · non-derivative	IndirectSee Footnote	135,492	Reported balance Holding disclosure · report date 2023-02-01 · row 12 Holding and transaction disclosures are not merged. 1 source row Row 12 · Balance 135,492 F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person is the investment manager to certain affiliated funds (collectively, the "Newtyn Funds"). The securities reported herein are held in the aggregate by the Newtyn Funds. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's beneficial ownership is limited to its pecuniary interest, if any, in such securities.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.61 to $19.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.69 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.94 to $18.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.795 to $17.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Pfenex Inc.

Report date September 30, 2020 · Filed October 02, 2020

Section 16 reporting ended · disclosed 2020-10-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2020-09-30 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-09-30 · Other · Disposed 3,850,000 · Balance 0 F1: Each share was tendered and sold to a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated for (i) $12.00 per share, in cash, and (ii) a non-transferrable contractual right to receive a contingent payment of up to $2.00 in cash, if a specified milestone is achieved, without interest and less any applicable withholding taxes. F2: The shares are held directly by Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE"). Newtyn Management, LLC, as the investment manager to NP and NTE, possesses the sole power to direct the vote and the sole power to direct the disposition all investment and dispositive power over the securities held by NP and NTE. Newtyn Management, LLC disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, NP, NTE or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Each share was tendered and sold to a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated for (i) $12.00 per share, in cash, and (ii) a non-transferrable contractual right to receive a contingent payment of up to $2.00 in cash, if a specified milestone is achieved, without interest and less any applicable withholding taxes.

F2: The shares are held directly by Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE"). Newtyn Management, LLC, as the investment manager to NP and NTE, possesses the sole power to direct the vote and the sole power to direct the disposition all investment and dispositive power over the securities held by NP and NTE. Newtyn Management, LLC disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, NP, NTE or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 12, 2020 Filed Aug 13, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	834	$3.49	$2,913.16	Disclosure SEC source: 0000899243-20-022283 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 587,205 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.45 to $3.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
August 12, 2020 Filed Aug 13, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,166	$3.49	$4,072.84	Disclosure SEC source: 0000899243-20-022283 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 805,717 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.45 to $3.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
August 11, 2020 Filed Aug 13, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	5,856	$3.45	$20,217.84	Disclosure SEC source: 0000899243-20-022283 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 586,371 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.35 to $3.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
August 11, 2020 Filed Aug 13, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	8,186	$3.45	$28,262.17	Disclosure SEC source: 0000899243-20-022283 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 804,551 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.35 to $3.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 22, 2020 Filed Jul 24, 2020 18:59 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	40,488	$3.04	$123,160.45	Disclosure SEC source: 0000899243-20-020427 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 580,515 F3 · acquired: The purchase of the securities referenced in this Form 4 were conducted in a private transaction between Gary Crocker and certain family members and affiliates as the sellers and each of Western Standard Partners, L.P., Western Standard Partners QP, L.P., Newtyn Partners, LP, and Newton Partners TE, LP as the purchasers. Gary Crocker is President and Chairman of Merrimack Pharmaceuticals, Inc. (the "Company"). Eric Andersen, a member of the Company's Board of Directors, is Managing Member of Western Standard LLC, the investment manager for each of Western Standard Partners L.P. and Western Standard Partners QP L.P. Noah Levy, a member of the Company's Board of Directors, is Managing Member of Newtyn Management, LLC, the investment manager for Newtyn Partners, LP, and Newton Partners TE, LP. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 22, 2020 Filed Jul 24, 2020 18:59 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	33,435	$3.20	$107,058.87	Disclosure SEC source: 0000899243-20-020427 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 540,027 F3 · acquired: The purchase of the securities referenced in this Form 4 were conducted in a private transaction between Gary Crocker and certain family members and affiliates as the sellers and each of Western Standard Partners, L.P., Western Standard Partners QP, L.P., Newtyn Partners, LP, and Newton Partners TE, LP as the purchasers. Gary Crocker is President and Chairman of Merrimack Pharmaceuticals, Inc. (the "Company"). Eric Andersen, a member of the Company's Board of Directors, is Managing Member of Western Standard LLC, the investment manager for each of Western Standard Partners L.P. and Western Standard Partners QP L.P. Noah Levy, a member of the Company's Board of Directors, is Managing Member of Newtyn Management, LLC, the investment manager for Newtyn Partners, LP, and Newton Partners TE, LP. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 22, 2020 Filed Jul 24, 2020 18:59 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	56,606	$3.04	$172,189.79	Disclosure SEC source: 0000899243-20-020427 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 796,365 F3 · acquired: The purchase of the securities referenced in this Form 4 were conducted in a private transaction between Gary Crocker and certain family members and affiliates as the sellers and each of Western Standard Partners, L.P., Western Standard Partners QP, L.P., Newtyn Partners, LP, and Newton Partners TE, LP as the purchasers. Gary Crocker is President and Chairman of Merrimack Pharmaceuticals, Inc. (the "Company"). Eric Andersen, a member of the Company's Board of Directors, is Managing Member of Western Standard LLC, the investment manager for each of Western Standard Partners L.P. and Western Standard Partners QP L.P. Noah Levy, a member of the Company's Board of Directors, is Managing Member of Newtyn Management, LLC, the investment manager for Newtyn Partners, LP, and Newton Partners TE, LP. F1 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 22, 2020 Filed Jul 24, 2020 18:59 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	46,745	$3.20	$149,677.49	Disclosure SEC source: 0000899243-20-020427 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 739,759 F3 · acquired: The purchase of the securities referenced in this Form 4 were conducted in a private transaction between Gary Crocker and certain family members and affiliates as the sellers and each of Western Standard Partners, L.P., Western Standard Partners QP, L.P., Newtyn Partners, LP, and Newton Partners TE, LP as the purchasers. Gary Crocker is President and Chairman of Merrimack Pharmaceuticals, Inc. (the "Company"). Eric Andersen, a member of the Company's Board of Directors, is Managing Member of Western Standard LLC, the investment manager for each of Western Standard Partners L.P. and Western Standard Partners QP L.P. Noah Levy, a member of the Company's Board of Directors, is Managing Member of Newtyn Management, LLC, the investment manager for Newtyn Partners, LP, and Newton Partners TE, LP. F1 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 21, 2020 Filed Apr 22, 2020 14:30 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	591	$3.25	$1,920.75	Disclosure SEC source: 0000899243-20-011149 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 506,592 F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 21, 2020 Filed Apr 22, 2020 14:30 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	833	$3.25	$2,707.25	Disclosure SEC source: 0000899243-20-011149 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 693,014 F1 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 20, 2020 Filed Apr 22, 2020 14:30 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	965	$3.25	$3,136.25	Disclosure SEC source: 0000899243-20-011149 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 506,001 F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 20, 2020 Filed Apr 22, 2020 14:30 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,360	$3.25	$4,420.00	Disclosure SEC source: 0000899243-20-011149 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 692,181 F1 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 07, 2020 Filed Apr 8, 2020 17:37 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	2,448	$3.03	$7,421.85	Disclosure SEC source: 0000899243-20-010517 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 505,036 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 07, 2020 Filed Apr 8, 2020 17:37 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	3,451	$3.03	$10,462.74	Disclosure SEC source: 0000899243-20-010517 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 690,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 06, 2020 Filed Apr 7, 2020 19:24 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	2,507	$3.00	$7,512.23	Disclosure SEC source: 0000899243-20-010465 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 502,588 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.975 to $3.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 06, 2020 Filed Apr 7, 2020 19:24 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	3,535	$3.00	$10,592.63	Disclosure SEC source: 0000899243-20-010465 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 687,370 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.975 to $3.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 03, 2020 Filed Apr 7, 2020 19:24 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	4,461	$2.59	$11,568.27	Disclosure SEC source: 0000899243-20-010465 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 500,081 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 03, 2020 Filed Apr 7, 2020 19:24 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	6,289	$2.59	$16,308.63	Disclosure SEC source: 0000899243-20-010465 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 683,835 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.